Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 22;10(10):1838.
doi: 10.3390/healthcare10101838.

Obesity as a Risk Factor for Severe COVID-19 in Hospitalized Patients: Epidemiology and Potential Mechanisms

Affiliations
Review

Obesity as a Risk Factor for Severe COVID-19 in Hospitalized Patients: Epidemiology and Potential Mechanisms

Scarleth Aburto et al. Healthcare (Basel). .

Abstract

SARS-CoV-2 infection is a global public health problem, causing significant morbidity and mortality. Evidence shows that obesity is a recognized risk factor for hospitalization, admission to critical care units, and the development of serious complications from COVID-19. This review analyzes the available epidemiological evidence that relates obesity to a higher risk of severity and mortality from COVID-19, examining the possible pathophysiological mechanisms that explain this phenomenon on a cellular and molecular level.

Keywords: COVID-19; SARS-COV-2; infection; obesity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Pathophysiology of complications associated with obesity in COVID-19. Obesity is a recognized risk factor for complications in SARS-Cov-2 infection, which is associated with various mechanisms. SARS-CoV-2 enters the cell through the interaction of the S protein with the ACE2 receptor expressed in various cell types. Proposed mechanisms include: (A) ACE2 expression in adipose tissue, which contributes to increased susceptibility to infection and viral systemic spread; (B) chronic inflammation and amplification of the pro-inflammatory response, characterized by a deregulation of the immune response associated with progression to severe and critical conditions characterized by multiple organ failure mediated by apoptosis and alteration of lung function, triggering different respiratory complications; and (C) endothelial damage and hypercoagulability, a phenomenon mediated by the direct cytotoxic action of the virus on the endothelial cell that expresses ACE2, generating endothelial disease and apoptosis. On the other hand, significant changes have been described in the expression of procoagulant proteins and regulation of fibrinolysis, release of microparticles derived from platelets and platelet activation induced by the generation of reactive oxygen species (ROS), which generates a state of hypercoagulability, predisposing the patient to the development of thrombosis.

Similar articles

Cited by

References

    1. Mapa de COVID-19—Johns Hopkins Coronavirus Resource Center. [(accessed on 6 July 2022)]. Available online: https://coronavirus.jhu.edu/map.html.
    1. Ruiz-Bravo A., Jiménez-Valera M. SARS-CoV-2 y Pandemia de Síndrome Respiratorio Agudo (COVID-19) [(accessed on 26 June 2022)];Ars Pharm. 2020 61:63–79. Available online: https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S2340-9894202....
    1. Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72,314 Cases from the Chinese Center for Disease Control and Prevention. [(accessed on 26 June 2022)];JAMA. 2020 323:1239–1242. doi: 10.1001/jama.2020.2648. Available online: https://jamanetwork.com/journals/jama/fullarticle/2762130. - DOI - PubMed
    1. Plasencia-Urizarri T.M., Aguilera-Rodríguez R., Mederos L.E.A. Comorbilidades y gravedad clínica de la COVID-19: Revisión sistemática y meta-análisis. [(accessed on 10 June 2022)];Rev. Habanera Cienc. Médicas. 2020 19:3389. Available online: http://www.revhabanera.sld.cu/index.php/rhab/article/view/3389.
    1. Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q., Ji R., Jia R., Wang H., Wang Y., et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. [(accessed on 26 June 2022)];Int. J. Infect. Dis. 2020 94:91–95. doi: 10.1016/j.ijid.2020.03.017. doi: 10.1016/j.ijid.2020.03.017. Available online: - DOI - DOI - PMC - PubMed

LinkOut - more resources